STK11 and KEAP1 co-mutations in KRAS-mutated NSCLC are associated with a poor prognosis and resistance to anti-PD1 and anti-PD-L1 blockade [30,31,32]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.